Abstract:This study aimed to evaluate the prognostic value of circulating tumor cells (CTCs) and CTC clusters, termed circulating tumor microemboli (CTM), detected in patients with locally advanced rectal cancer (LARC) undergoing standard neoadjuvant chemoradiotherapy. From September 2014 to August 2015, the clinicopathological variables, such as gender, age, tumor location, depth of invasion, lymphatic invasion, distant metastasis, TNM stage, CTCs and CTM enumeration before chemoradiotherapy, of 42 newly acquired and histopathologically confirmed LARC patients were collected from the Fudan University Shanghai Cancer Center. All patients were followed up for survival until the end of December 2019. Statistical analysis focused on the associations between CTCs counts, CTM and clinicopathological variables. Overall survival (OS) and progression-free survival (PFS) among different prognostic factors were calculated using the Kaplan–Meier method, and the differences between the survival curves were compared by using the log-rank test. Factors of prognostic significance were investigated with the multivariate Cox regression analysis. CTCs and CTM were detected in 32% (13/42) and 57% (24/42) of patients, respectively. CTC-positive rate was positively correlated with the depth of invasion, lymphatic invasion, distant metastasis, TNM stage, and serum CEA level (P<0.05 for all). However, no significant difference was found between CTC-positive and other clinicopathological variables (P>0.05 for all), such as gender, age, tumor location, and tumor de-differentiation. CTCs counts gradually increased with the advancement of depth of invasion (P = 0.002), lymphatic invasion (P = 0.004), distant metastasis (P = 0.007), TNM stage (P = 0.001), serum CEA level (P = 0.001), and decreased tumor de-differentiation (P = 0.011). Furthermore, the Kaplan–Meier survival curves showed that patients with CTC-positive had a significantly unfavorable PFS (28 vs. 46 months, P = 0.001) and OS (36 vs. 50 months, P = 0.003). The multivariate Cox regression analyses revealed that the presence of CTCs before chemoradiotherapy was an independent factor for unfavorable PFS (hazard ratio (HR) 2.682, P = 0.017, 95% confidence interval (CI) 1.193–6.029) and OS (HR 2.790, P = 0.048, 95% CI 1.010–7.705) in LARC patients. This study provided an evidence that the presence of pretreatment CTCs may be valuable for predicting survival outcome, and CTCs was associated with unfavorable survival in LARC patients treated with neoadjuvant chemoradiotherapy.

Survival Implications Of Pretreatment Pelvic Ct In Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy And Surgery

To Be or Not to Be: Significance of Lymph Nodes on Pretreatment CT in Predicting Survival of Rectal Cancer Patients

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

The Value of Lymph Node Ratio in the Prediction of Rectal Cancer Patient Survival after Preoperative Chemoradiotherapy.

Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study

Prognostic Value of Circulating Tumor Cells and Circulating Tumor Microemboli in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy

MRI‐based parameters and clinical risk factors to predict lymph node metastasis in patients with ypT0 rectal cancer after neoadjuvant chemoradiotherapy

The Influence of Neoadjuvant Therapy for the Prognosis in Patients with Rectal Carcinoma: a Retrospective Study

Rectal Cancer Survival for Residual Carcinoma In Situ Vs. Pathologic Complete Response After Neoadjuvant Therapy

[Efficacy Assessment of Preoperative Radiochemotherapy and Analysis of Associated Factors in Rectal Cancer].

Identifying High Risk Factors in Locally Advanced Rectal Cancer Patients with Ypt0-2n0 after Preoperative Chemoradiation

Survival Benefit of Preoperative Versus Postoperative Radiotherapy in Metastatic Rectal Cancer Treated with Definitive Surgical Resection of Primary Tumor: A Population Based, Propensity Score-Matched Study.

Survival outcomes of different neoadjuvant treatment regimens in patients with locally advanced rectal cancer and MRI‐detected extramural venous invasion

Radiomics Features on Radiotherapy Treatment Planning CT Can Predict Patient Survival in Locally Advanced Rectal Cancer Patients

Role of postoperative radiotherapy in pT3N0 rectal cancer: A risk-stratification system based on population analyses.

Effect of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) and Non-Operative Strategy on Outcomes of Distal Rectal Cancer Patients with Clinically Positive Lateral Pelvic Lymph Node

Prognostic Factors of Rectal Cancer Treated with Multimodality Therapy Based on Surgery

High Preoperative Peripheral Blood Neutrophil Predicts Poor Outcome in Rectal Cancer Treated with Neoadjunctive Chemoradiation Therapy.

Prognostic value of lateral lymph node metastasis in pretreatment MRI for rectal cancer in patients undergoing neoadjuvant chemoradiation followed by surgical resection without lateral lymph node dissection: A systemic review and meta-analysis

Impact Of Neoadjuvant And Adjuvant Radiotherapy On Disease-Specific Survival In Patients With Stages Ii-Iv Rectal Cancer